moxifloxacin has been researched along with Primary Peritonitis in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (41.67) | 29.6817 |
| 2010's | 6 (50.00) | 24.3611 |
| 2020's | 1 (8.33) | 2.80 |
| Authors | Studies |
|---|---|
| Adeniyi, ET; Chen, S; Drießen, D; Ioerger, TR; Kalscheuer, R; Kruppa, M; Müller, TJJ; Rehberg, N; Sommer, GA; Tasch, BOA; Wang, L; Wolf, K; Zhu, K | 1 |
| Brandt, CT; Figueiredo Filho, CA; Maior, GIS; Marquis, VWPB; Mascena, GV; Moura, LCRV; Paz, ARD | 1 |
| Brandt, CT; Gadelha, DN; Melo, MC; Oliveira, TK | 1 |
| Alder, J; Arvis, P; De Waele, JJ; Hussain, T; Kruesmann, F; Solomkin, JS; Tellado, JM; Weiss, G | 1 |
| Dong, J; Johnson, DW; Qu, Z; Tian, X; Wang, H; Xu, R; Yang, Z | 1 |
| Hampel, B; Lippert, H; Muehlhofer, E; Reimnitz, P; Weiss, G | 1 |
| Chen, MJ; Hampel, B; Ma, EL; Solomkin, J; Zhao, YP | 1 |
| Hsueh, PR; Huang, YT; Liao, CH; Liu, CY; Lu, CL | 1 |
| Cheadle, W; Lee, JT; Napolitano, LM; Nichols, RL | 1 |
| Chen, X; Guo, X; Shi, G; Wang, H; Wang, S; Zhang, X | 1 |
| Delesen, H; Kubitza, D; Rink, AD; Stass, H; Vestweber, KH | 1 |
| Eremina, LV; Iakovlev, SV; Nazarov, VV; Ramishvili, VSh | 1 |
1 review(s) available for moxifloxacin and Primary Peritonitis
| Article | Year |
|---|---|
Clinical update on the use of moxifloxacin in the treatment of community-acquired complicated intraabdominal infections.
Topics: Anti-Bacterial Agents; Aza Compounds; Bacterial Infections; Community-Acquired Infections; Fluoroquinolones; Humans; Moxifloxacin; Peritonitis; Quinolines | 2010 |
6 trial(s) available for moxifloxacin and Primary Peritonitis
| Article | Year |
|---|---|
Efficacy and safety of moxifloxacin in hospitalized patients with secondary peritonitis: pooled analysis of four randomized phase III trials.
Topics: Adult; Aged; Anti-Bacterial Agents; Double-Blind Method; Drug Administration Schedule; Female; Fluoroquinolones; Hospitalization; Humans; Injections, Intravenous; Male; Middle Aged; Moxifloxacin; Peritonitis; Prospective Studies; Treatment Outcome | 2014 |
Intraperitoneal Vancomycin Plus Either Oral Moxifloxacin or Intraperitoneal Ceftazidime for the Treatment of Peritoneal Dialysis-Related Peritonitis: A Randomized Controlled Pilot Study.
Topics: Administration, Oral; Anti-Bacterial Agents; Ceftazidime; Drug Therapy, Combination; Female; Fluoroquinolones; Humans; Male; Middle Aged; Moxifloxacin; Peritoneal Dialysis; Peritoneum; Peritonitis; Pilot Projects; Prospective Studies; Vancomycin | 2017 |
Moxifloxacin for the treatment of patients with complicated intra-abdominal infections (the AIDA Study).
Topics: Abdominal Abscess; Administration, Oral; Adult; Aged; Amoxicillin-Potassium Clavulanate Combination; Anti-Infective Agents; Appendicitis; Aza Compounds; Bacterial Infections; Ceftriaxone; Drug Therapy, Combination; Female; Fluoroquinolones; Gastrointestinal Diseases; Humans; Infusions, Intravenous; Intestinal Perforation; Male; Metronidazole; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Peritonitis; Prospective Studies; Quinolines | 2009 |
Moxifloxacin is non-inferior to combination therapy with ceftriaxone plus metronidazole in patients with community-origin complicated intra-abdominal infections.
Topics: Adult; Anti-Bacterial Agents; Asia; Aza Compounds; Ceftriaxone; Community-Acquired Infections; Double-Blind Method; Drug Therapy, Combination; Female; Fluoroquinolones; Humans; Male; Metronidazole; Middle Aged; Moxifloxacin; Peritonitis; Quinolines; Treatment Outcome | 2009 |
Pharmacokinetics and peritoneal penetration of moxifloxacin in peritonitis.
Topics: Adult; Aged; Anti-Bacterial Agents; Area Under Curve; Ascitic Fluid; Aza Compounds; Biological Availability; Female; Fluoroquinolones; Humans; Infusions, Intravenous; Male; Middle Aged; Moxifloxacin; Peritoneum; Peritonitis; Quinolines | 2006 |
[Efficacy of moxifloxacin in the treatment of secondary peritonitis].
Topics: Adult; Aged; Anti-Infective Agents; APACHE; Aza Compounds; Female; Fluoroquinolones; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Peritonitis; Quinolines; Treatment Outcome | 2006 |
5 other study(ies) available for moxifloxacin and Primary Peritonitis
| Article | Year |
|---|---|
Nature-Inspired (di)Azine-Bridged Bisindole Alkaloids with Potent Antibacterial
Topics: Alkaloids; Animals; Anti-Bacterial Agents; Cell Line; Cell Survival; Female; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Indoles; Methicillin-Resistant Staphylococcus aureus; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Peritonitis; Pyruvate Kinase; Rabbits | 2020 |
Role of moxifloxacin-dexamethasone in cardiac histomorphometric findings among Wistar rats from infected mothers.
Topics: Animals; Animals, Newborn; Dexamethasone; Disease Models, Animal; Female; Fluoroquinolones; Heart; Moxifloxacin; Myocardium; Organogenesis; Peritonitis; Pregnancy; Pregnancy Complications; Prospective Studies; Rats; Rats, Wistar | 2018 |
Severe autogenously fecal peritonitis in Wistar rats with permanent bilateral carotid occlusion. Response to intra peritoneal moxifloxacin combined with dexamethasone.
Topics: Animals; Anti-Bacterial Agents; Anti-Inflammatory Agents; Carotid Artery, Common; Dexamethasone; Drug Combinations; Feces; Fluoroquinolones; Models, Animal; Moxifloxacin; Peritonitis; Rats, Wistar; Reproducibility of Results; Time Factors; Tissue Adhesions; Treatment Outcome | 2014 |
In vitro activities of moxifloxacin and tigecycline against bacterial isolates associated with intraabdominal infections at a medical center in Taiwan, 2001-2006.
Topics: Anti-Bacterial Agents; Aza Compounds; Bacteria; Bacterial Infections; Bacterial Proteins; beta-Lactamases; Community-Acquired Infections; Cross Infection; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Minocycline; Moxifloxacin; Peritonitis; Quinolines; Taiwan; Tigecycline | 2009 |
Activity of sitafloxacin against extracellular and intracellular Staphylococcus aureus in vitro and in vivo: comparison with levofloxacin and moxifloxacin.
Topics: Animals; Anti-Bacterial Agents; Aza Compounds; Cell Line; Chromatography, High Pressure Liquid; Disease Models, Animal; Dose-Response Relationship, Drug; Extracellular Space; Fluoroquinolones; Intracellular Space; Levofloxacin; Mice; Mice, Inbred ICR; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Peritonitis; Quinolines; Staphylococcal Infections; Staphylococcus aureus; Time Factors | 2012 |